Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 148 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Liposomal bupivacaine for post-operative pain in children	Liposomal bupivacaine (Exparel)	Post-operative pain	Pain Relief	2021	View \| Download
Loncastuximab Tesirine for relapsed or refractory diffuse large B-cell lymphoma – third line	Loncastuximab Tesirine (ADCT-402; Lonca; Zylonta)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2021	View \| Download
Magrolimab in addition to azacitidine for myelodysplastic syndromes - First-line	Azacitidine (Vidaza; CC-486) , Magrolimab (Hu5F9-G4)	Myelodysplastic syndrome (MDS)	Haematological Cancer and Lymphomas	2021	View \| Download
Maralixibat for cholestatic liver disease in patients with Alagille syndrome	Maralixibat chloride (SHP625)	Alagille syndrome	Genetic Disorders	2021	View \| Download
Mavacamten for hypertrophic cardiomyopathy	Mavacamten (MYK-461)	Hypertrophic cardiomyopathy (HCM)	Cardiovascular System	2021	View \| Download
Mavorixafor for WHIM syndrome	Mavorixafor (X4P-001)	WHIM syndrome	Genetic Disorders , Immunology	2021	View \| Download
Mirikizumab for the treatment of moderately to severely active ulcerative colitis	Mirikizumab (LY3074828)	Ulcerative colitis	Gastroenterology	2021	View \| Download
Mobocertinib for locally advanced or metastatic NSCLC	TAK-788 (AP32788; Mobocertinib)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Mosunetuzumab for relapsed or refractory B-cell follicular lymphoma – third-line and greater	Mosunetuzumab (BTCT4465A)	Follicular lymphoma	Haematological Cancer and Lymphomas	2021	View \| Download
Natalizumab (subcutaneous injection) for highly active relapsing remitting multiple sclerosis	Natalizumab (BG00002; Tysabri; Antegren; AN-100226; ELND-002)	Multiple sclerosis (MS)	Neurology	2021	View \| Download